Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CAR T Cells G-Rex®100M

Publication Date: June 29, 2022

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells

Cas-CLOVER, a dimeric nuclease fusing the Clo051 nuclease domain to catalytically dead Cas9, edits resting primary human T cells with very low off-target activity. Combined with piggyBac delivery of a BCMA-specific CAR, it was used to knock out TRBC and B2M and produce allogeneic CAR-T cells. Purified products showed TCR knockout of 99% or higher and on-target indels of 94% to 99%. Off-target indels at 19 GUIDE-seq-nominated sites across eight donors ranged between 0.012% and 0.089% on average. Some donors yielded over 60% stem cell memory T cells. The cells killed BCMA-expressing tumor cells in vitro and eliminated tumors in mice for seven of 10 donors.

Download Now →

Author: Blair B. Madison, Deepak Patil +13 more

Publications T-Cells G-Rex®100

Publication Date: June 21, 2022

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK- 186

TAK-186, a protease-activated T cell engager built on the COBRA design and directed against EGFR, regressed established human tumor xenografts in mice, and the effect depended on cleavage inside the tumor. Precleaved TAK-186 killed EGFR-expressing LoVo, HT29 and SCC25 cells in vitro with EC50 values of 0.37, 0.54 and 0.07 pM. Dosed every 3 days for seven doses with human T cells, it regressed SCC25 tumors at 4 μg/kg and LoVo and HT29 tumors at 100 μg/kg. Precleaved drug cleared quickly and did not regress LoVo tumors. In HT29 tumors, 71% of TAK-186 was cleaved by 168 hours, versus 11% in plasma.

Download Now →

Author: Danielle E Dettling, Eilene Kwok +12 more

Publications CAR T Cells, γδ T

Publication Date: June 16, 2022

Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth

Transient mRNA electroporation of a first-generation BCMA CAR (αBCMAz) into ex vivo expanded Vγ9Vδ2 T cells produced potent, antigen-specific anti-myeloma activity in vitro and in vivo. Transfection efficiency reached 70% to 86%, with CAR expression peaking one day after electroporation and becoming hardly detectable by day 6. The modified cells lysed BCMA-positive KMS-11, KMS-18, OPM-2 and U266 lines more strongly than NKG2Dz CAR cells, released IFN-γ and mobilised CD107a only against BCMA-positive targets. In KMS-11-Luc xenografted NSG mice given Zometa plus weekly doses of 1 × 10^7 cells for three weeks, femur radiance fell from 8.1 × 10^7 and 6.0 × 10^7 to 2.3 × 10^7, and median survi…

Download Now →

Author: Xi Zhang, Yu Yang Ng +6 more

Publications CAR T Cells

Publication Date: June 9, 2022

The Past, Present, and Future of Non-Viral CAR T Cells

Non-viral gene transfer with Sleeping Beauty (SB) and piggyBac (PB) transposons, mRNA and nanocarriers is positioned as a cheaper, more flexible route to CAR T cell manufacturing than viral vectors. Transposon plasmids are estimated to cost 5 to 10 times less than the viral process, and SB integrates in a close-to-random pattern, whereas PB prefers sites near transcription start sites. A multicenter phase I/II trial (NCT03389035) treated 21 patients with B-ALL relapsed after allogeneic transplant using SB-engineered CARCIK-CD19 cells; acute GvHD was never observed. In the PB-based CARTELL study, two of 10 treated patients developed malignant CAR T cell tumors, so the authors recommend lim…

Download Now →

Author: Alex Moretti, Marianna Ponzo +4 more

Publications NK Cells, T-Cells, VST Cells

Publication Date: June 2, 2022

HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy

The HydrAd platform, a helper-dependent adenovirus (HDAd) carrying several immunomodulatory transgenes in one vector, expressed functional molecules from multiple immune classes in solid tumor cell lines. A library covered chemokines, cytokines, checkpoint minibodies, co-stimulatory ligands, engagers and a suicide gene. Ad5, Ad5/3 and Ad5/35 capsids transduced most tested tumor lines with similar efficacy. A 41BBL vector made breast cancer cells twofold more susceptible to tumor-antigen-specific T cells, and engager supernatants raised lysis, for example MUC1.BiTE from 16% to 75%. Co-infection with an oncolytic adenovirus raised IL15 from undetectable to 34 pg/mL at 10 vp/cell. Three-tran…

Download Now →

Author: Amanda Rosewell Shaw, Caroline Porter +3 more

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: May 31, 2022

A Simple and Robust Single-Step Method for CAR-Vd1 gdT Cell Expansion and Transduction for Cancer Immunotherapy

Stimulating PBMC depleted of abTCR-positive and CD56-positive cells with OKT-3 and IL-15 alone expands Vd1 gdT cells efficiently in a single step. In 6-well G-Rex® vessels, six donors all reached more than 400-fold Vd1 expansion over 20 days, and three exceeded 1,000-fold. The expanded cells killed T-cell leukemia, cervical, neuroblastoma, myeloid and neuroblastoma-type targets without CAR engineering. Retroviral transduction with a B7H3-28z CAR reached about 50% efficiency across nine donors. CAR-Vd1 cells then showed antigen-specific proliferation, expanding 4-fold against B7H3-positive Jurkat cells versus about 2-fold for controls, along with antigen-dependent IFN-g production. A highe…

Download Now →

Author: Gabrielle M. Ferry, Charles Agbuduwe +6 more

Publications T-Cells G-Rex®100M-CS

Publication Date: May 30, 2022

Enabling Allogeneic T Cell-Based Therapies: Scalable Stirred-Tank Bioreactor Mediated Manufacturing

A closed stirred-tank bioreactor platform with alternating tangential flow perfusion expanded donor T cells 167-fold in 14 days, compared with 28-fold in a G-Rex® 100M-CS run from the same donor. Viable density reached 33.5 × 10^6 cells/mL on day 14 with perfusion at one vessel volume per day started on day 8, and viability stayed above 96%. Expanded cells were about 80% central memory, with low senescence and exhaustion markers. In-vessel magnetic depletion removed more than 99% of CD4+ cells at 17% input and 96.87% at 52.4%, and residual beads fell to 0.001% after 120 minutes. Closed concentration with ekko gave 7-fold and 79% recovery; kSep gave 7.65-fold and 69% recovery.

Download Now →

Author: Himavanth Gatla, Nicholas Uth +5 more

Publications TIL Cells G-Rex®100

Publication Date: May 23, 2022

Salt- inducible kinase 3 protects tumor cells from cytotoxic T- cell attack by promoting TNF- induced NF- κB activation

Tumor cells use salt-inducible kinase 3 (SIK3) to resist killing by cytotoxic T cells, because SIK3 sustains TNF-driven NF-κB signaling and pro-survival gene expression. An siRNA screen of 2887 genes in PANC-1 pancreatic cancer cells cocultured with patient-derived TILs, confirmed with survivin-specific T-cell clones, identified 108 candidate genes, with SIK3 among the strongest hits. Genetic or drug-based SIK3 inhibition increased T-cell killing of pancreatic, breast, colorectal and melanoma cells, and in NSG mice, SIK3-deficient melanoma tumors grew more slowly after TIL transfer. Neutralizing TNF fully rescued SIK3-depleted cells from T-cell-induced death. In 178 TCGA pancreatic cancer…

Download Now →

Author: Antonio Sorrentino, Ayse Nur Menevse +28 more

Publications CTL Cells, T-Cells G-Rex®24 Well Plate

Publication Date: May 23, 2022

Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP

Gene editing of T cells from patients with X-linked lymphoproliferative disease (XLP) restored SAP expression and SAP-dependent immune functions to healthy-control levels. TALEN, Cas9 and Cas12a nucleases all cut the SH2D1A locus efficiently, and an AAV6 donor inserted SAP cDNA at exon 1. Serum-free transduction allowed a much lower AAV dose. TALEN gave the highest homology-directed repair, up to 50% GFP-positive cells, against about 30% for Cas9 and Cas12a. In T cells from five XLP patients, averages of 45% and 46% of lymphocytes were corrected by GFP and SAP staining. Edited cells regained restimulation-induced cell death sensitivity, T:B cell signalling and EBV-directed killing in one…

Download Now →

Author: Benjamin C. Houghton, Neelam Panchal +8 more

Publications CAR T Cells G-Rex®10

Publication Date: May 4, 2022

BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity

Adding exogenous GOT2, a mitochondrial metabolic enzyme, to a GPC3-targeted CAR (BOXR1030) improved CAR T cell antitumor activity in aggressive solid tumor xenograft models. Two low doses of 1 × 10^6 CAR+ cells caused durable regressions of Hep3B tumors for about 100 days, whereas the CAR alone had little to no activity. BOXR1030 cells showed higher intracellular aspartate and AST activity, a less-differentiated phenotype, lower stress and exhaustion gene expression, and better proliferation under hypoxia or low glucose. GPC3 was detected in more than 30% of hepatocellular carcinoma, lung squamous, Merkel cell and liposarcoma samples tested. A clinical trial is planned.

Download Now →

Author: Taylor L. Hickman, Eugene Choi +14 more

Publications CAR T Cells, TCR T Cells G-Rex®500M

Publication Date: April 29, 2022

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies

Three NIH case studies show that engineered T cell products can be manufactured in culture bags, on an automated platform or in G-Rex® bioreactors, with the choice guided by target dose, scalability and cost. CD30 CAR-T cells grown in culture bags reached a median of 2.2 × 10^9 cells at harvest on Day 7 across 25 products. CD19/CD22 bispecific CAR-T cells made on the CliniMACS Prodigy yielded a median of 1.883 × 10^9 cells, and all 24 products were successfully manufactured. E7 TCR T cells, whose target dose is orders of magnitude higher than for CAR-T cells, were expanded in G-Rex® bioreactors for a 14-day rapid expansion, giving a median of 123.3 × 10^9 cells and 491-fold expansion at t…

Download Now →

Author: Hannah W. Song, Robert P. Somerville +2 more

Publications VST Cells G-Rex®10

Publication Date: April 29, 2022

Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products

Culturing SARS-CoV-2-specific T cells with IL-15 plus IL-7 instead of the standard IL-4 plus IL-7 gave a better balanced product for adoptive therapy. In a 96-well microexpansion screen of five cytokine cocktails with PBMCs from 9 convalescent donors, adding IL-7 or IL-6 to IL-15 raised CD8+ T cells by 24%–40% over non-IL-15 culture, and IL-15 + IL-7 also preserved total T cell and CD4+ expansion. RNA sequencing of CD4+ and CD8+ cells from 4 donors showed the strongest antiviral interferon-stimulated gene enrichment with IL-15 + IL-7 (NES 1.82 and 1.83), whereas IL-4 induced genes negatively regulating host defense. In G-Rex® 10 bioreactors, mean fold expansion was 3.2 versus 1.9 for IL-1…

Download Now →

Author: Jessica Durkee-Shock, Christopher A. Lazarski +12 more